Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Apr 2018 This trial has been completed in Spain, according to European Clinical Trials Database
- 01 Mar 2018 Planned End Date changed from 21 Mar 2018 to 23 Apr 2018.
- 01 Mar 2018 Planned primary completion date changed from 14 Apr 2018 to 23 Apr 2018.